Author:
Lu Yuanjun,Chan Yau-Tuen,Tan Hor-Yue,Li Sha,Wang Ning,Feng Yibin
Abstract
AbstractEpigenetics is dynamic and heritable modifications to the genome that occur independently of DNA sequence. It requires interactions cohesively with various enzymes and other molecular components. Aberrant epigenetic alterations can lead to inappropriate onset of genetic expressions and promote tumorigenesis. As the epigenetic modifiers are susceptible to extrinsic factors and reversible, they are becoming promising targets in multiple cancer therapies. Recently, various epi-drugs have been developed and implicated in clinical use. The use of epi-drugs alone, or in combination with chemotherapy or immunotherapy, has shown compelling outcomes, including augmentation of anti-tumoral effects, overcoming drug resistance, and activation of host immune response.
Funder
Research Council of the University of Hong Kong
Wong’s donation
Gaia Family Trust of New Zealand
Research Grants Council, University Grants Committee
Health and Medical Research Fund
Enhanced new staff start-up fund
Preemptive retention fund
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Molecular Medicine
Cited by
299 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献